<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5771">
  <stage>Registered</stage>
  <submitdate>24/02/2016</submitdate>
  <approvaldate>24/02/2016</approvaldate>
  <nctid>NCT02704429</nctid>
  <trial_identification>
    <studytitle>A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris</studytitle>
    <scientifictitle>An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PRN1008-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pemphigus Vulgaris</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PRN1008

Experimental: PRN1008 - Open-label PRN1008, 12 weeks; 12 week follow up


Treatment: drugs: PRN1008
PRN1008, oral dose, 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of treatment-emergent adverse events at 12 weeks - The incidence of treatment-emergent adverse events (TEAEs), including clinically significant changes in physical examination, laboratory tests, and vital signs.</outcome>
      <timepoint>12 weeks treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Control of disease activity at 4 weeks - The proportion of subjects who are able to achieve control of disease activity (CDA) within 4 weeks of starting PRN1008 treatment without the need for doses of prednisone or prednisolone &gt;0.5 mg/kg.</outcome>
      <timepoint>4 weeks treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to control of disease activity (CDA) - Time to control of disease activity (CDA) as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</outcome>
      <timepoint>12 week treatment; 12 week follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to end of consolidation phase - Time to end of consolidation phase as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</outcome>
      <timepoint>12 week treatment; 12 week follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to complete remission - Time to complete remission as defined in European Academy of Dermatology2015 Pemphigus S2 Guideline</outcome>
      <timepoint>12 week treatment; 12 week follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to relapse after PRN1008 treatment discontinuation - Time to relapse after PRN1008 treatment discontinuation as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</outcome>
      <timepoint>12 week treatment; 12 week follow up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV
             (PDAI 8 to 45) that are either:

               -  newly diagnosed patients (i.e. naïve to an effective induction treatment regimen)
                  for whom an initial period of PRN1008 monotherapy is judged clinically
                  acceptable, or

               -  relapsing patients, for whom an initial period of PRN1008 monotherapy, or
                  combination therapy with any of low dose corticosteroid (= 10 mg/day),
                  azathioprine, mycophenolate mofetil, sulfasalazine and dapsone, is judged
                  clinically acceptable, provided cessation of azathioprine, mycophenolate mofetil,
                  sulfasalazine, and dapsone within two to four weeks is anticipated</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating women

          -  A history of malignancy of any type, other than surgically excised non-melanoma skin
             cancers or in situ cervical cancer within 5 years before the day of dosing

          -  Use of immunologic response modifiers with the following periods prior to Day 1: 1
             week: cyclophosphamide; 4 weeks: Kinaret (anakinra) and Enbrel (etanercept); 12 weeks:
             Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept),
             Actemra (tocilizumab), Cimzia (certolizumab), Cosentyx (secukinumab), intravenous
             immunoglobulin, plasmapheresis; 6 months: Rituxan/MabThera (rituximab), ofatumumab,
             any other anti-CD20 antibody

          -  Use of &gt;10 mg per day of oral prednisolone for more than 1 week within 4 weeks prior
             to Day 1 (inhaled and mucosal [for symptomatic treatment of oral lesions]
             corticosteroids are allowed)

          -  Has received any investigational drug (or is currently using an investigational
             device) within the 30 days before receiving the first dose of study medication, or at
             least 5 times the respective elimination half-life time (whichever is longer)

          -  Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1

          -  History of solid organ transplant

          -  Positive for screening for HIV, hepatitis B (surface and core antibodies unrelated to
             vaccination), or hepatitis C (anti-HCV antibody confirmed with Hep C RNA)

          -  History of active or latent tuberculosis (TB) infection (subjects must also test
             negative using the QuantiFERON® test to be eligible for the study)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Premier Specialists - Kogarah</hospital>
    <hospital>Sinclair Dermatology - East Melbourne</hospital>
    <hospital>Royal Melbourne, Dermatology Office - Melbourne</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3050 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaly</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat-Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Principia Biopharma, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Principia Biopharma Australia Pty Ltd.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus
      vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy,
      and with conventional immunosuppressive "rescue treatment", if indicated. The duration of
      therapy will be 12 weeks, followed by 12 weeks of follow up.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02704429</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven G Gourlay, MBBS, PhD</name>
      <address>Principia Biopharma</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Steven G Gourlay, MBBS PhD</name>
      <address />
      <phone>650-416-7700</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>